Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 7/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3881128 | 0.98 | CYP3A4 (0.40) | CYP3A4ASIC3PNMTADRA2AADRA2B | |
| SCHEMBL4016057 | 0.88 | HTR2C (0.42) | HTR2CHTR2AHTR2BADRB1 | |
| SCHEMBL1996608 | 0.86 | HTR2C (0.42) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL3884326 | 0.84 | HTR2C (0.39) | ASIC3HTR2CHTR2AHTR2BADRB1 | |
| SCHEMBL20038293 | 0.83 | PNMT (0.41) | CYP3A4ASIC3PNMTADRA2AADRA2B | |
| SCHEMBL13853275 | 0.82 | CYP3A4 (0.42) | CYP3A4ASIC3PNMTADRA2AADRA2B | |
| SCHEMBL29875556 | 0.74 | SORT1 (0.40) | ADRA2AADRA2BADRA2CHTR2CHTR2A | |
| SCHEMBL16220610 | 0.74 | CYP3A4 (0.45) | CYP3A4ASIC3PNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL2913654 | 0.74 | ASIC3 (0.46) | CYP3A4ASIC3HTR2CHTR2AHTR2B | |
| SCHEMBL23388029 | 0.73 | CYP3A4 (0.44) | CYP3A4ASIC3PNMTADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220641-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023064587-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-02-16 | — | — | US | disclosed |
| CN-107207532-B | Nitroimidazole derivatives against tuberculosis | 南京明德新药研发股份有限公司 | 2019-07-30 | — | — | CN | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-2183250-B1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2183250-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090170885-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170885-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009018466-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018466-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CYP3A4 276/4885ASIC3 580/4885PNMT 1801/4885 |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | CYP3A4 1325/4885ASIC3 4584/4885PNMT 199/4885 |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | CYP3A4 844/4885ASIC3 4741/4885PNMT 442/4885 |
| US-20090170885-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNQ5, KCNJ1 | CYP3A4 750/4885ASIC3 368/4885PNMT 1919/4885 |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | CYP3A4 1325/4885ASIC3 4584/4885PNMT 199/4885 |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | BET1, BRD4, BRD3 | CYP3A4 1325/4885ASIC3 4584/4885PNMT 199/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | CYP3A4 844/4885ASIC3 4741/4885PNMT 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.